SFC
NBIX icon

SYM Financial Corp’s Neurocrine Biosciences NBIX Stock Holding History

SYM Financial Corp’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203K Sell
1,207
-735
-38% -$109K 0.02% 379
2026
Q1 		$256K Sell
1,942
-97
-5% -$12.9K 0.03% 252
2025
Q4 		$289K Buy
2,039
+281
+16% +$40.7K 0.03% 234
2025
Q3 		$247K Buy
+1,758
New +$238K 0.03% 259

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SYM Financial Corp's NBIX Position: Q2 2026 in Review

SYM Financial Corp reduced its Neurocrine Biosciences (NBIX) stake by 38% in Q2 2026, selling an estimated $109K and leaving 1,207 shares worth $203K. The position accounts for 0.02% of the portfolio, ranked #379.

SYM Financial Corp first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. The position peaked at $289K in Q4 2025. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • SYM Financial Corp held 1,207 shares of Neurocrine Biosciences worth $203K as of Q2 2026.
  • SYM Financial Corp sold 735 Neurocrine Biosciences shares in Q2 2026, an estimated $109K.
  • Neurocrine Biosciences made up 0.02% of SYM Financial Corp's portfolio in Q2 2026, its #379 holding.
  • SYM Financial Corp first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • SYM Financial Corp's Neurocrine Biosciences position peaked at $289K in Q4 2025.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on SYM Financial Corp's 13F filing for Q2 2026, filed 4 Aug 2026.